Timberlyne Therapeutics

Timberlyne Therapeutics is a clinical stage biopharmaceutical company dedicated to developing and commercializing therapies for autoimmune diseases. The company leverages its team's extensive drug development expertise to acquire and apply best-in-class assets against compelling targets. Timberlyne's lead program, CM313, is an IgG1 monoclonal antibody with enhanced cytotoxicity that targets CD38, a protein highly expressed on plasma cells, NK cells, and other immune cells. By targeting CD38, CM313 modulates multiple arms of the immune system, leading to rapid and durable responses across various autoimmune diseases. Timberlyne aims to develop CM313 for a broad range of autoimmune indications, addressing significant unmet medical needs. Founded in 2024, the company has raised $180 million from leading life sciences investors to advance its mission of bringing life-changing medicines to patients. Timberlyne was formed by Mountainfield Venture Partners in partnership with Keymed Biosciences and has exclusive development and commercialization rights to CM313 worldwide, excluding greater China.

Keywords: biopharmaceutical, autoimmune, therapies, monoclonal antibody, CD38, cytotoxicity, immune modulation, drug development, commercialization, life sciences.